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Abbreviation 
 
ACT Artemisinin-based Combination Therapies 
CERMEL Centre de Recherche Médicale de Lambaréné 
DDT Dichloro-Diphenyl-Trichloroethane 
DNA              Desoxyribonucleic Acid 
dNTPs Desoxy Ribonucleotides 
ELISA  Enzyme Linked Immunosorbent Assay 
FU  Follow-Up 
GIA               Growth Inhibition Assay 
GMAP Global Malaria Action Plan 
GMEP Global Malaria Eradication Program 
HeLa  Named after the patient Henrietta Lacks 
HRP2  Histidine-Rich Protein 2 
HTS  High Throughput Screening 
IC50  50% Inhibitory Concentration 
i.p.  Intraperitoneal 
i.v.  Intravenous 
i.m   Intramuscular 
NMCP National Malaria Control Program 
nmol  Nanomole 
nM  Nanomolar 
PCR  Polymerase Chain Reaction 
P.falciparum Plasmodium falciparum 
RBC  Red Blood Cell 
RDT  Rapid Diagnostic Test 
rRNA  ribosomal Ribonucleic Acid 
TBS              Thick Blood Smear 
UN  United Nation 
WHO  World Health Organization 
mL  milliliter 
µg  microgram 
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Kurzfassung 
Malaria ist eine Infektionskrankheit, welche durch einen Parasiten der Gattung 
Plasmodium verursacht wird. Im Jahr 2013 gab es geschätzte 198 Millionen 
Krankheits- und 584000 Todesfälle durch Malaria, von denen die meisten in Afrika 
auftraten. 
Als Therapie der Wahl für die unkomplizierte Infektion mit Plasmodium falciparum hat 
sich die Verwendung von Artemisinin-basierten Kombinationstherapien (ACTs) 
etabliert. Die Wirksamkeit von ACT gegen P. falciparum ist sehr gut belegt, jedoch 
gibt es nur wenige Daten, welche die Wirksamkeit von ACT gegen andere 
humanpathogene Spezies des Malariaerregers zeigen, da hier weiterhin meistens 
das Medikament Chloroquin zur Anwendung kommt und bisher klinische Studien 
fehlen. Jedoch finden sich in hochendemischen Gebieten neben P. falciparum auch 
Infektionen durch andere Spezies von Plasmodium. In der Praxis ist eine exakte 
mikroskopische Speziesidentifikation seltenerer Plasmodium-Spezies bei Mono- und 
Mischinfektionen sowie der Nachweis von residualen Parasiten nach der 
Chemotherapie oftmals nicht möglich. Die Verfügbarkeit einer Breitbandmedikation 
würde die Behandlung von seltenen (non-falciparum) Plasmodium-Spezies und 
Mischinfektionen erleichtern.  
Diese Arbeit zeigt Daten über die Wirksamkeit von Artemether-Lumefantrin (AL), ein 
häufig in Zentralafrika eingesetztes ACT, bei unkomplizierten non-falciparum oder 
Mischinfektionen in Lambaréné, Gabun. Vierzig Patienten mit durch P. malariae oder 
P. ovale verursachter unkomplizierter Malaria sowie Mischinfektionen mit P. 
falciparum wurden drei Tage lang mit AL behandelt und für 28 Tage beobachtet. Die 
Therapie führte bei allen teilnehmenden Patienten zu einer raschen Reduktion der 
Parasitämie und gutem klinischem Ansprechen. Das Spektrum unerwünschter 
Ereignisse (adverse events) war gering und transient. Alle Patienten waren am Ende 
der Studie gesund. Nach 28 Tagen lag auch die Reduktion der Parasitenlast bei 100 
% bei guter Verträglichkeit der Medikation, was für die Verwendung von AL als 
Behandlung der unkomplizierten Malaria in Gabun bei non-falciparum oder 
Mischinfektionen spricht. Die Ergebnisse der mikroskopischen Identifikation von non-
falciparum Spezies waren trotz etablierter Qualitätskontrolle nur unzureichend.  Von 
39 Proben, welche mikroskopisch als non-falciparum oder Mischinfektionen deklariert 
wurden,  konnten nur 19 durch die PCR als solche bestätigt werden. Als Grund 
hierfür kann unter anderem die häufig niedrige Parasitämie der Proben benannt 
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werden.  Dies wiederum unterstreicht den Nutzen einer breit wirksamen 
Malariatherapie.  
Der zweite Teil dieser Arbeit befasst sich mit der in vitro Wirksamkeit von 
Fluoreszenzfarbstoffen gegen P. falciparum Parasiten. Manche heute verwendeten 
antimikrobiellen Wirkstoffe, welche eine Breitbandwirkung besitzen, stammen 
ursprünglich von molekular veränderten künstlichen Farbstoffen ab und aufgrund des 
zunehmenden Auftreten von Resistenzen gegen die aktuell verwendeten 
Malariamedikamente ist die Entwicklung von neuen Chemotherapeutika notwendiger 
denn je. 
Die ursprüngliche Idee die Wirksamkeit von fluoreszierenden Farbstoffen gegen P. 
falciparum zu testen entwickelte sich aus in vivo Markierungsversuchen. Während 
dieser Versuche wurde eine bemerkenswerte antiparasitäre Wirksamkeit mancher 
Farbstoffe beobachtet. Durch diese Beobachtung motiviert, wurde die Wirksamkeit 
von vierzehn fluoreszierenden Farbstoffen in in vitro Wachstums-Tests für die zwei 
Laborstämme von P. falciparum  3D7 und Dd2  systematisch untersucht.  
Fünf der verwendeten Farbstoffe (Rhodamine B, MitoTracker Red, and DiOC6, 
Hoechst33342, SYTO 9) hatten eine vergleichbare Wirksamkeit zur Kontrollgruppe 
mit Chloroquin und verhielten sich zudem nicht zytotoxisch bei Anwendung an 
menschliche HeLa Zellen. Daraufhin wurden die Farbstoffe Rhodamine B und DiOC6 
im Maus-Model untersucht, jedoch zeigte sich hier eine hohe Toxizität von DiOC6. 
Rhodamine B war weniger toxisch, führte aber nicht zu einer relevanten Reduktion 
der Parasitämie. Ungeachtet dessen zeigen diese Testversuche, dass die 
Untersuchung der antiparasitären Eigenschaften von Farbstoffen eine interessante 
Option darstellt um neue effiziente pathogen spezifische Substanzen zu finden. Die 
bereits erwähnte Notwendigkeit von breit wirksamen Malariawirkstoffen in 
Endemiegebieten ist unumstritten. Dabei sollte die Anforderung an das Wirkspektrum 
nicht nur die Elimination von verschiedenen Plasmodiumspezies, sondern auch das 
jeweilige Entwicklungsstadium des Plasmodiums umfassen.   
AL besitzt zwar eine sehr gute Wirksamkeit gegen verschiedene Parasitenspezies, 
wirkt jedoch nicht gegen die prä-erythrozytären Stadien des Parasiten (Sporozoiten 
und infizierte Hepatozyten) und nur unzureichend gegen Gametozyten. Farbstoffe 
sind eine heterogene Stoffgruppe, die diesem erweiterten Wirksamkeitsspektrum 
entsprechen könnten. Es wurde gezeigt, dass Methylenblau tatsächlich diese 
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Anforderungen erfüllt. Die Untersuchung von größeren Farbstoff Datenbanken 
könnte zur Entwicklung von neuen breit wirksamen Wirkstoffen beitragen.  
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Summary  
Malaria, an infectious disease caused by a parasite of the genus Plasmodium, was 
responsible for about 198 Million cases and 584 000 deaths in 2013, mainly in Sub-
Saharan Africa.  
The first line treatment for uncomplicated Plasmodium falciparum infections are 
artemisinin combination therapies (ACTs). Although the efficacy of ACTs against P. 
falciparum has been well documented, there is only anecdotal evidence of efficacy of 
ACTs against other human Plasmodium species because chloroquine is still 
recommended and commonly used. However, in highly endemic regions non-
falciparum species can occur together with P. falciparum and, moreover, exact 
microscopic species identification and detection of residual parasites is usually not 
possible in those settings. Availability of broadly acting drugs would ease clinical 
management of suspected non-falciparum and mixed infections.  
This thesis presents data on the efficacy of artemether-lumefantrine (AL), a widely 
used ACT, against uncomplicated non-falciparum or mixed-species malaria in 
Lambaréné, Gabon and assesses the performance of microscopy in an African 
routine laboratory setting. Forty patients presenting with uncomplicated malaria 
caused by P. malariae, P. ovale or a mixed infection (including P. falciparum) were 
treated with a three days AL regimen and were followed up to 28 days after start of 
the treatment. All evaluable patients presented an adequate clinical and 
parasitological response. All adverse events were mild or moderate and resolved by 
the end of the follow-up. The parasitological cure rate was 100% and the drug was 
well tolerated. These findings support the use of AL for the treatment of 
uncomplicated malaria in Gabon, even when non-falciparum or mixed infections are 
suspected. Microscopic identification of Plasmodium species other than P. falciparum 
did not perform well. From 39 samples microscopically determined as non-falciparum 
or mixed infection, only 19 were confirmed by PCR. This might be due to the very low 
parasitaemia found in most cases and underlines the need for the development of 
broadly acting antimalarials.   
The second part of this thesis reports on the in vitro activity of fluorescent dyes 
against cultured malaria parasites. The emergence of resistance against most of the 
drugs in current use urges the development of new antimalarial compounds. Since 
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several antimicrobials were derived from molecular modification of synthetic dyes, 
which often have a broad spectrum of activity, screening of dyes may represent an 
interesting strategy to identify novel antimalarial lead structures. The original 
motivation to screen fluorescent dyes in Plasmodium were in vivo labeling 
experiments. Here, a remarkably high antiparasitic activity was noted for some 
compounds. Hence, the activity of fourteen fluorescent dyes was systematically 
investigated by in vitro growth assays using the two laboratory P. falciparum strains 
3D7 and Dd2. Five had an activity comparable to the control drug chloroquine and 
were not cytotoxic against human HeLa cells (Rhodamine B, MitoTracker Red, and 
DiOC6, Hoechst33342, SYTO 9). Rhodamine B and DiOC6 were further tested in a 
mouse model but DiOC6 was toxic and Rhodamine B, although less toxic, did not 
lead to a notable reduction of parasitaemia. Despite of this, this pilot experiment 
shows that pre-screening for staining properties may be an interesting way to build 
highly efficient pathogen-specific compound libraries. 
 
There is a need for broadly acting antimalarial drugs. This requirement includes multi-
stage activity as well as activity against different parasite species. AL showed high in 
vivo activity against different Plasmodium species, but does not act against pre-
erythrocytic stages (sporozoites and infected hepatocytes) and reduces gametocytes 
only modestly. Dyes are a group of chemically heterogeneous compounds that may 
extent the spectrum of activity. In fact, the dye methylene blue was shown to meet 
many of the requirements. Investigation of larger dye libraries may result in highly 
interesting novel antimalarial compounds and may lead to the development of novel, 
broadly acting drugs.  
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Résumé 
Le paludisme est une maladie infectieuse causée par un parasite du genre 
Plasmodium. En 2013, cette maladie était responsable d’environ 584000 décès 
principalement en Afrique subsaharienne. Les traitements de première ligne pour les 
infections à Plasmodium falciparum (P. falciparum) sont les thérapies combinées à 
base d’artémisinine (ACT). Bien que l’efficacité des ACTs contre P. falciparum a été 
clairement démontrée, il n’existe que des preuves anecdotiques de l’efficacité des 
ACTs contre les autres espèces de paludisme humain et la chloroquine est toujours 
le traitement recommandé dans ces cas-là. Cependant, les espèces non-falciparum 
peuvent souvent apparaitre de façon concomitante avec P. falciparum et de plus,  
l’identification des espèces s’avèrent toujours difficile. Ce serait ainsi un avantage 
important d’avoir un traitement unique pour toutes les espèces de paludisme. C’est 
pourquoi la première partie de cette thèse propose d’évaluer l’efficacité d’artemether-
lumefantrine (AL), une ACT couramment utilisée contre les infection paludiques non 
compliquées, non-falciparum ou bien mixtes à Lambaréné, Gabon.  
Quarante patients présentant un paludisme non compliqué provoqué par P. malariae, 
P. ovale ou bien mixtes (incluant P. falciparum) ont été traités avec un traitement à 
l’AL de trois jours et ont été suivi pendant 28 jours. Tous les patients évaluables 
présentaient une réponse clinique et parasitologique adéquat au jour 28. Tous les 
effets indésirables ont été d’intensité légère ou modérée et ont été résolus au jour 
28. Le taux de guérison au niveau parasitologique a été de 100% et le traitement a 
été bien toléré ce qui supporte l’utilisation de AL pour le traitement de tous les cas de 
malaria non-compliqués sans prendre en compte l’espèce. L’identification 
microscopique des espèces de Plasmodium autres que P. falciparum n’a pas été très 
performante. Sur 39 échantillons déterminés comme des infections non-falciparum 
ou mixtes par microscopie, seule 19 ont pu être confirmés par PCR. Cela peut être 
dû à la faible parasitémie et souligne le besoin pour des antipaludiques à large 
spectre d’action.   
Dans la deuxième partie de cette thèse nous évaluerons l’activité de colorants 
fluorescents contre des souches de P. falciparum adaptées à la culture. 
L’émergence de résistances à la plupart des médicaments en usage incite au 
développement rapide de nouvelles chimiothérapies.  De nombreux médicaments 
antimicrobiens dérivent à l’origine de la modification moléculaire de colorants 
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synthétiques. Avec ce travail, nous voulons relancer l’utilisation de colorants comme 
critère de présélection pour la découverte de nouveaux composés actifs. Nous avons 
évalué l’activité de quatorze colorants fluorescents contre deux souches de 
laboratoire de P. falciparum, 3D7 et Dd2. Cinq colorants ont eu une activité 
comparable au contrôle (chloroquine) et n’étaient pas cytotoxiques contre les cellules 
humaines HeLa (Rhodamine B, MitoTracker Red, and DiOC6, Hoechst 33342, SYTO 
9).   
La Rhodamine B et DiOC6 ont été testés sur un modèle murin. DiOC6 était très 
toxique et Rhodamine B, bien que moins toxique, n’a pas réussi à entrainer une 
diminution de la parasitémie. Malgré cela, cette étude pilote montre que la 
présélection pour les propriétés colorantes des molécules peut être un moyen 
intéressant de construire des chimiothèques spécifiques du pathogène.  
Il y a un besoin en médicaments antipaludiques à large spectre d’action. Ce besoin 
inclus une activité contre des stades multiples ainsi qu’une activité contre différentes 
espèces de parasites. AL a montré une très bonne activité contre différentes espèces 
mais n’agit pas contre les stades pre-érythrocytaires et ne réduit la gamétocytémie 
que de manière modeste. Les colorants sont un groupe de composés chimiques 
hétérogènes qui peuvent étendre le spectre d’activité. En fait, le colorant bleu de 
méthylène a montré qu’il répondait à un grand nombre de ces exigences. 
L’investigation de larges bibliothèques de colorants peut aboutir à de nouveaux 
composés antipaludiques très intéressant et peut conduire au développement de 
nouveaux médicaments à large spectre d’action.    
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1. Introduction 
1.1. Epidemiology and burden of the disease 
Malaria is an infectious disease caused by an Apicomplexa parasite of the genus 
Plasmodium. It is transmitted by the bite of an infected female Anopheles mosquito. 
There are more than 200 different species of Plasmodium known, five of which cause 
naturally acquired malaria in humans: Plasmodium falciparum (P. falciparum), 
Plasmodium vivax (P. vivax), Plasmodium malariae (P. malariae), Plasmodium ovale 
(P. ovale) and Plasmodium knowlesi (P. knowlesi). A recent study based on genetic 
observation suggests that P. ovale can be differentiated in two species, a classic type 
(P. ovale curtisi) and a variant type (P. ovale walikeri) [1]. P. falciparum is the most 
deadly parasite and predominates in Sub-Saharan Africa but is also prevalent in 
Southeast Asia and South-America. Although P. vivax is considered as benign tertian 
malaria, it can be associated with significant morbidity and even mortality. A study 
conducted in Papua-New Guinea showed that 9% of children infected with P. vivax 
presented with severe malaria against 12% of children infected with P. falciparum [2]. 
Moreover P. vivax accounts for almost half of the cases outside Africa and can 
remain in the liver in a dormant stage as hypnozoite [3–5]. P. ovale is mainly 
distributed in Sub-Saharan Africa and in some islands of the Western Pacific and 
account for less than 5% of the malaria cases [6]. It is usually benign but can also 
develop hypnozoites, dormant liver stages. P. malariae is usually benign and has a 
low prevalence. Its distribution corresponds to P. falciparum to which it is often found 
as co-infection. However, P. malariae infections often remain undetected if no 
molecular diagnostic method is used.    
P. knowlesi was first described in the 30’s infecting Macaca fascicularis monkeys. It 
has been shown in 1932 that the parasite was also able to infect humans and it was 
even used to induce fever in the treatment of neurosyphillis [7]. Very few natural 
cases have been reported until 2004 [8], when it was shown that active transmission 
of the parasite from macaques to humans is present in Southeast Asia [7]. Although 
no naturally occurring human-to-human transmission has been confirmed so far, a 
host-switch of P. knowlesi from macaques to humans is not impossible and should be 
2 
 
closely monitored [9]. P. knowlesi can also lead to severe illness with symptoms 
similar to P. falciparum severe malaria [11]  
Malaria is one of the major health problems in tropical and subtropical regions. In 
2013, 198 million cases were reported and the number of deaths was estimated to be 
584 000 according to WHO, 90% were in the African region and 78% in children 
under 5 years. [12]. These figures are estimates and slightly changed assumptions 
lead to significantly higher numbers [13]. Malaria accounts for 5% of deaths of 
children under the age of five globally and, with 16% in Africa, is a major contributor 
to the disease burden of highly endemic regions.  
Beside this, malaria has a huge socioeconomic impact on the country affected by the 
disease. It has been estimated that the disease slows the economic growth of African 
countries by 1.3% a year. This is a consequence of the morbidity of the disease, 
which reduces the productivity of the population. It also discourages economic 
investment because of the risk of low productivity of the labor forces. Moreover, it 
challenges the health care system through additional expenses, this is especially 
relevant for economically weak countries with a poorly developed health sector [15].  
1.2. Pathology of the disease 
The life cycle of the parasite includes a sexual phase (sporogony) in the female 
mosquito and an asexual phase (schizogony) in the human host (Figure 1). An 
infected female mosquito feeds on a human host and inoculates sporozoites, which 
directly migrate to the liver. There they bind to heparin sulfate proteoglycans and 
glide along the surface of the sinusoidal endothelium and finally cross it through 
Kupffer cells. They transmigrate through several hepatocytes before invasion and 
becoming sessile. Within the host cell sporozoites divide and develop into schizonts, 
which form daughter cells called merozoites. This phase is called hepatic, pre-
erythrocytic or exo-erythrocytic and is clinically silent (asymptomatic). It ends with the 
release of merosomes (merozoites containing vesicles) into the blood stream. 
Merozoites egress from the merosome and invade red blood cells (RBC) where the 
parasites develop into trophozoites and subsequently schizonts. After completion of 
maturation, merozoites are released in the blood stream, which invade new 
erythrocytes. Some parasites can differentiate in female or male gametocytes and, if 
ingested by a female mosquito, mate, develop into new sporozoites and start the 
cycle again.  
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The symptoms of malaria occur during the erythrocytic phase of the cycle. Typically, 
symptoms are cyclic and peak shortly after merozoites are released into the blood 
stream. The symptoms are not specific and include fever, chills, headache, vomiting, 
fatigue, abdominal discomfort, muscle and joint ache, anemia, splenomegaly. In P. 
falciparum malaria, severe symptoms can occur: coma (cerebral malaria), 
prostration, convulsions, metabolic acidosis, severe anemia, hypoglycemia, acute 
renal failure or acute pulmonary oedema. Even with treatment, the case fatality in 
severe malaria can reach 20% [16].   
 
 
Figure 1: Life cycle of the malaria parasite [17] 
1.3. Malaria control policy 
In 1955, WHO started a first Global Malaria Eradication Program (GMEP) aiming to 
eradicate malaria in all endemic country except Sub-Saharan Africa and 
Madagascar. The strategy was to eliminate the vector through spraying with dichloro-
diphenyl-trichloroethane (DDT) in order to prevent transmission. Chloroquine was 
used as first line treatment and because of its efficacy and its low price, it was given 
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without laboratory confirmation of malaria. Other control strategies such as the use of 
bed nets or the draining of mosquitoes breeding marshes were abandoned [18]. 
However, DDT was found to be toxic and resistance started to develop in the 
mosquito population. Although it is still used in some tropical countries in the absence 
of a good alternative, its use is limited to indoor residual spraying. Additionally, P. 
falciparum chloroquine resistance emerged from independent foci and spread in the 
60s and 70s to an almost universal level. Nowadays, chloroquine cannot be used to 
treat P. falciparum malaria in almost all epidemiological relevant areas anymore [19]. 
Despite some success and advances, WHO recognized that eradication was not 
feasible in many countries and that a strategy of control with the aim to reduce 
morbidity and mortality would be more appropriate. As a consequence, the program 
was stopped in 1969. In the 70s and 80s, economic restrictions and a decrease in 
funding for malaria control, resulted in a severe increase of the burden of malaria in 
some countries [18]. Meanwhile, the WHO focused on research and development of 
new tools for malaria control and thus created a program in the mid 1970s; the 
Program for Research and Training in Tropical Diseases (TDR) [18]. In 1998, the 
WHO launched the Roll Back Malaria initiative with its strategy to reduce malaria 
morbidity and mortality by implementing global coverage and strengthening local 
health system [20]. Among the targets of WHO is the reduction of global malaria 
death to zero and a reduction of global malaria cases by 75% from 2010 to 2015. 
WHO’s strategy comprises two main approaches: malaria prevention through malaria 
vector control and better diagnosis and treatment.  The fight against malaria is also 
one of the eight Millennium Development Goals from the United Nation which were 
established in 2000 with the objective to halt and begin to reverse the incidence of 
malaria by 2015 [21].   
1.4. Malaria treatment 
During the campaign for malaria eradication in the 60s, chloroquine was the first line 
treatment because of its efficacy and its low price. Today, the drug has almost 
vanished from the market in endemic countries and is no more effective against P. 
falciparum infections in all relevant endemic areas [19]. 
In the late 60s, the Chinese government launched a large research program in order 
to find an alternative to chloroquine. Plants and their extracts used in traditional 
medicine were screened for their activity. Among them were extracts of Artemisia 
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annua, a plant used for centuries in traditional medicine that contains the 
endoperoxide artemisinin as the antimalarial principle. However it took a long time 
before artemisinin arrived on the global market, notably because it had to go through 
a full clinical development program to ensure that it was efficacious and not toxic. 
Moreover it was expensive to produce and thus not suitable for developing countries 
[22]. But thanks to a decrease in production cost its use has widely extended and 
since 2006 the first line treatments for P. falciparum uncomplicated malaria 
recommended by the WHO are Artemisinin based combination therapies (ACTs): 
artemether plus lumefantrine, artesunate plus amodiaquine, artesunate plus 
mefloquine and artesunate plus sulfadoxine-pyrimethamine (AS-SP). Because of its 
short half-life and to prevent development of resistance it is recommended to always 
use artemisinin and its derivatives in combination with partner drugs. Second line 
treatments consist of ad-hoc combinations of artesunate or quinine in combination 
with an antibiotic such as tetracycline, doxycycline or clindamycin. In case of 
pregnancy, quinine plus clindamycin is recommended during the first trimester and 
ACTs are recommended for the second and third trimester. For travelers returning to 
non-endemic countries, the following treatments are recommended: atovaquone-
proguanil, artemether-lumefantrine, quinine plus doxycycline or clindamycin. For the 
treatment of severe malaria, it is recommended to use artesunate intravenously (i.v.) 
or intramuscularly (i.m.) or, if not available, the recommended alternative is 
artemether or quinine i.v. or i.m. [16].  
For the treatment of P. vivax, chloroquine in combination with primaquine is still the 
treatment of choice. ACTs can also be used in combination with primaquine, which is 
the only licensed and available drug acting on hypnozoites. However due the 
development of resistance to pyrimethamine, the combination artesunate plus 
sulfadoxine-pyrimethamine (AS-SP) might be less effective against P. vivax in many 
places [16]. 
The recommended treatment of P. ovale and P. malariae infection is the same as for 
P. vivax, namely chloroquine but without primaquine in the case of P. malariae as this 
species does not produce hypnozoites [16].  
Despite the recommendation of the WHO for the treatment of non-falciparum 
species, ACTs are often used for the treatment of all forms of malaria. This is due to 
the fact that non-falciparum species and especially P. malariae and P. ovale often 
occur concomitantly with P. falciparum. Moreover they are often difficult to identify in 
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absence of molecular diagnostic test such as Polymerase Chain Reaction (PCR) and 
low-grade infection with P. falciparum cannot be ruled out. Nevertheless, only 
anecdotal evidence is present to show that ACTs are also efficient against P. 
malariae, P. ovale and mixed-species infection.  
1.5. The problem of resistance  
Resistance is defined as the ability for a parasite strain to survive or develop despite 
the administration of a drug at a dose equal or higher than the normally 
recommended dose. In the case of malaria, it has to be clarified that the active drug 
must be able to reach the parasite within the infected cell, for the duration of the time 
necessary for its normal action [23]. If the efficacy of a drug is decreased because 
the active substance did not reach the parasite, we talk about medicament failure. 
This is for example the case if some individuals metabolize the drug too quickly to 
ensure a sufficient concentration or because the RBC membrane becomes 
impermeable to the drug because of an increase pH due to parasite metabolites.  
P. falciparum resistance to chloroquine is spread worldwide and, except in very few 
areas, chloroquine should not be used for the treatment of P. falciparum infections 
anymore. Artemether-lumefantrine remains highly effective worldwide except 
Cambodia, where resistance against many ACTs have already been reported [24]. In 
addition, high treatment failure rates have been reported in six African countries who 
adopted artesunate-amodiaquine as first line treatment, most likely due to resistance 
against the partner drug. Artesunate-mefloquine has lower efficacy in the Mekong 
region where mefloquine resistance is already widespread. Moreover, several in vitro 
and in vivo studies showed a decreased sensitivity of P. falciparum to artesunate, 
notably in Bangladesh, Thailand and Cambodia [25–27].  
Chloroquine treatment failure against P. vivax has been reported since 1989 from 
Indonesia, Myanmar, India and South-America. Moreover higher dosage of 
primaquine are now often required to clear hypnozoite in Southeast Asia, South-
America and South-Pacific, which suggests the presence of primaquine tolerant 
parasites [19]. P. vivax resistance to sulfadoxine-pyrimethamine (SP) is frequent, 
hence SP-treatment is not recommended for P. vivax infections [16].  
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No case of resistance has been reported for P. ovale but some cases of treatment 
failure with chloroquine and quinine have been reported for P. malariae [28–30]. 
However in absence of reliable study, the existence or level of drug resistance in 
these two parasite species is questionable.  
1.6. Rational for the development of new anti-malarial drugs 
Antimalarial drugs belong to only few classes of chemical scaffolds. Nowadays, 
mainly eight different chemotypes are in clinical use, which act on five ways of action 
(see Figure 2) [31]. For example, chloroquine, piperaquine and amodiaquine are 4-
aminoquinoline molecules; mefloquine as well as halofantrine and lumefantrine are 
analogues of quinine. In fact, all these molecules are related to the active compound 
of the cinchona bark [32]. Even if the mode of action of many of these drugs is not 
completely understood, it is assumed, and in some cases experimentally shown, that 
resistance develops faster if molecules are similar. Indeed, resistance against many 
of these drugs developed quickly after they have been introduced. For example 
resistance to mefloquine arose only a few years after its introduction at the border of 
Cambodia and Thailand, partly because of its long half-life, which leads to extended 
exposure of parasites to sub-therapeutic mefloquine concentrations, but also of 
preexisting quinine resistance [33]. 
Therefore, it is commonly accepted that there is a constant need for new drugs to 
circumvent this resistance problem. E.g. the UN millennium report recommends: “It is 
important to maintain a sufficiently large, high-quality pipeline of antimalarial 
compounds to ensure sustainability in medicine discovery and development.” [21] 
The important challenges in the fight against malaria are that the parasite exist under 
different forms (asexual and gametocytes), can stay dormant for several years in the 
case of P. vivax and P. ovale (hypnozoites) or can remain at low level in 
asymptomatic carriers and that five different species can infect humans. To address 
these challenges, an ideal drug should be broadly acting which means that it could 
eliminate all five species of Plasmodium as well as the gametocytes and the liver 
forms.  
It is often assumed from case report that a drug effective against P. falciparum is also 
effective against P. malariae and that a drug effective against P. vivax is also 
effective against P. ovale but usually no hard evidence is present. This can be a 
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problem as the strategy to eliminate malaria often focus on P. falciparum and P. vivax 
but if the prevalence of these both species is reduced, we do not know how the 
transmission of P. malariae and P. ovale will evolve [34]. Therefore more clinical 
studies are required about these neglected species and they should be considered 
when developing new drugs.  
A broadly acting drug should dramatically reduce the transmission of the parasites. It 
should be radically effective to kill all replicating asexual parasites as well as the 
gametocytes and the hypnozoites. It should moreover be safe and well tolerated to 
allow administration to vulnerable groups and asymptomatic carriers (e.g. in mass 
administration campaigns). Such a drug would also prevent the development of 
resistance [35]. Currently no drug combines all these characteristics, therefore 
research and development of new drugs is important. Moreover, for drugs already in 
clinical use, evidence through clinical trials is needed to assess their efficacy against 
all malaria species, including P. ovale and P. malariae.  
 
 
Figure 2: Clinically used antimalarial chemotypes and their way of action. (From 
Spitzmüller A et al. [31] ) 
1.7. Screening of dyes for their antiplasmodial activity  
The history of malaria chemotherapy and the history of synthetic dyes are heavily 
intertwined. In fact, one could claim that the dye industry is founded in malaria 
research. The first synthetic dye, mauvein, was discovered in 1856 by William Henry 
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Perkin when he was trying to synthesize quinine. This was a commercial success 
and Perkin developed many other dyes used in the industry [36]. Synthetic dyes 
revolutionized the textile industry but also modern chemotherapy. Paul Ehrlich was 
using dyes to differentially stain tissue, cells or microbes and developed the concept 
that a dye staining specifically a microorganism could also have a specific toxic effect 
by interacting with it. Thus, when he noticed that methylene blue stains specifically P. 
falciparum, he tried to treat two malaria patients with this compound and successfully 
cured them [37]. He also had success in the treatment of trypanosomiasis with trypan 
red [36].  
Generally speaking, the pharmaceutical industry developed mainly from the dye 
industry after World War I. For example the pharmaceutical company Bayer derived 
from the German dye company Ig Farben. The sulfonamide drugs, precursors of 
sulfadoxine, were developed in this company from a textile dye [38]. After WWI, the 
German government funded a search for quinine substitute in order to supply the 
troops. The research was performed by Ig Farben, where thousands of compounds 
were tested. One of the most promising was mepacrine derived from the dye acridine 
[22]. In 1934 Resochin was synthesized and tested but because of its presumed 
toxicity it was not developed further. It was only during World War II that the 
American army obtained the compound and developed it as chloroquine.  
Nowadays, the strategy to develop new drugs is not anymore based on staining 
properties but still follows Paul Ehrlich’s concept:  
“We must search for magic bullets. We must strike the parasites and the parasites 
only, if possible, and to do this, we must learn to aim with chemical substances!”  
The conventional approach is high throughput screening of large chemical libraries in 
order to find compounds acting on a specific target. It is also possible to pre-select 
compounds by multiple steps e.g. through the modifications of known 
pharmacophores. This latter approach is not the best in the context of malaria 
because of the previously mentioned resistance and cross-resistance problems.  
In this work, the use of staining properties as a pre-selection criterion in order to 
discover new anti-malarial compounds was successfully revived.  
1.8. Objective of the thesis 
The thesis is divided in two parts: 
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1.8.1. Evaluation of the antiplasmodial activity of fluorescent dyes   
The objectives of this work were:  
1) to identify novel antimalarial structures with a broad spectrum of activity.  
2) to investigate specific staining as a pre-selection criterion to discover new anti-
malarial compounds.  
To prove the concept, fourteen commercially available dyes were assessed: 
MitoTracker red, MitoTracker green, Daspei, DiOC6, Rhodamine 123, Rhodamine B, 
JC1, and SYTO 18, all of which stain specifically mitochondria, Hoechst 33342, 
Acridine Orange, SYBR Green I, SYTO 9 which stain nucleic acids and 
carboxyfluorescein diacetate [CFDA] and CFDA-succinimidyl ester [CFDA-SE], two 
molecules binding proteins. Their anti-plasmodial activity was tested with an in vitro 
test against two laboratory strains of P. falciparum, the chloroquine sensitive 3D7 and 
the chloroquine resistant Dd2. In a second step, the toxicity against human cells was 
evaluated for the dyes with good antiplasmodial activity.  
1.8.2. Prospective evaluation of artemether-lumefantrine for the 
treatment of non-falciparum and mixed-species malaria in Gabon 
The efficacy of ACT therapy has been shown against P. falciparum and P. vivax but 
no study has been done so far to investigate their efficacy against P. malariae and P. 
ovale. However, because these parasites often occur as co-infection together with P. 
falciparum and frequently remain undetected or miss-classified because they are 
difficult to distinguish from other species by classical diagnostics methods, these two 
species are often treated with ACTs. To develop recommendations for the treatment 
of non-falciparum and mixed infections, it is important to know the efficacy of ACT 
treatment against these two rare and neglected species. Artemether-lumefantrine is 
the most widely used ACT.  
The objectives of this work were:  
1) The primary objective of this work was to determine the activity of Artemether-
lumefantrine against non-falciparum or mixed-species malaria infection in 
Gabon.  
2) The secondary objective was to investigate the reliability of microscopic 
determination of Plasmodium species under routine conditions was assessed.    
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2. Results 
2.1. In vitro activity of fluorescent dyes against asexual blood stages of 
Plasmodium falciparum (publication 1) 
In order to find new classes of antimalarial drugs, I tried to revive the use of staining 
property as pre-selection criterion in the discovery of new drugs. Fourteen 
commercially available fluorescent dyes which stain specifically mitochondria 
(MitoTracker red, MitoTracker green, Daspei, DiOC6, Rhodamine 123, Rhodamine B, 
JC1, and SYTO 18), nucleic acids (Hoechst 33342, Acridine Orange, SYBR Green I, 
SYTO 9) or proteins (carboxyfluorescein diacetate [CFDA], CFDA-succinimidyl ester 
[CFDA-SE]) were selected. The antiplasmodial activity of the dyes were tested 
against two laboratory strains of P. falciparum, the chloroquine sensitive 3D7 and the 
multi-resistant Dd2 strain, and their activity was compared with those of two 
reference drugs, chloroquine and methylene blue. Parasite multiplication in the 
presence of serial dilutions of candidate dyes or controls was measured by the 
Histidine-Rich-Protein 2 assay as described previously [39] and an 50% Inhibitory 
concentration (IC50) was calculated by regression analysis of log concentration 
response curve. Two different incubation times of either three or six days have been 
tested. The six days assay has been performed as described previously in order to 
see if the substance acted on the subsequent cycle (delayed death phenomenon) 
[40]. An ideal drug should act specifically against the parasite and not against human 
cells. Therefore cytotoxicity of dyes with the highest antiplasmodial activity was 
evaluated in human HeLa cells by a neutral red assay [41]. The dyes with the highest 
activity against P. falciparum strains 3D7 and Dd2 were Hoechst 33342 (7.2 nM and 
16.3 nM), MitoTracker red (8.2 nM and 15.9 nM), DiOC6 (11.4 nM and 20.8 nM), 
SYTO 9 (20.5 nM and 36.1 nM) and Rhodamine B (20.6 nM and 26.1 nM, 
respectively). CFDA and CFDA-SE had very low or no activity against both strains 
(IC50 above 333µM and 55µM respectively) (table 1). All dyes with high activity were 
at least 50 times less toxic against human HeLa cells than against P. falciparum.  
 
Dyes IC50±SD  IC90±SD  
3 days 6 days 3 days 6 days 
Hoechst 33342 7.2±3.1 18.9±11.9 14.0±8.8 25.8±17.3 
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16.3±11.2 28.0±2.6 72.7±107.9 36.5±0.8 
MitoRed 8.2±9.6 10.6±6.1 14.1±19.5 15.3±8.4 
15.9±10.9 6.3±7.3 44.8±24.0 9.0±0.2 
DiOC6 11.4±8.1 17.3±17.1 17.4±9.4 24.1±23.9 
20.8±12.2 168.3±301.8 55.7±31.5 229.0±401.4 
Rhodamine B 20.6±12.6 19.2±10.8 40.7±12.4 29.5±8.9 
26.1±15.3 69.5±113.2 101.1±34.6 117.2±194.8 
SYTO 9 20.5±20.0 23.1±44.9 101.5±105.
7 
41.0±64.2 
36.1±17.7 4.9±0.73 261.7±114.
1 
10.8±3.9 
JC1 107.8±66.3 177.0±55.0 170.6±84.8 279.8±95.36 
100.1±96.9 121.0±128.2 269.9±252.
2 
162.0±156.3 
MitoGreen 115.5±149.9 187.1±197.2 331.9±407.
5 
245.2±215.0 
148.9±102.7 103.8±58.0 1521±2335 150.8±87.9 
Rhodamine 123 387.7±208.6 189.2±235.1 870.3±567.
6 
490.3±584.0 
140.7±117.4 287.2±316.0 2335±3893 414.2±450.7 
Acridine Orange 465.7±274.9 691.9±391.8 1772±1057 691.9±391.8 
166.0±75.9 208.2±22.5 620.4±379.
6 
278.8±31.4 
Daspei 327.2±327.2 502.7±797.2 2026±2364 834.7±1298 
591.3±405.8 270.6±267.2 55046±798
10 
831.3±1315 
SYTO 18 1751±969.8 873.1±482.1 5016±3186 1916±1144 
387.1±207.6 636.3±413.5 1865±381.1 1141±880.2 
SYBR Green I 2585±4693 11497±17785 4669±8532 17897±28028 
2100±1024 1218±583.2 14062±173
91 
1792±872.5 
CFDA-SE > 55 µM > 55 µM > 55 µM > 55 µM 
> 55 µM > 55 µM > 55 µM > 55 µM 
CFDA > 333 µM > 333 µM > 333 µM > 333 µM 
> 333 µM > 333 µM > 333 µM > 333 µM 
Methylene blue 7.8±3.2 14.3±10.7 13.3±1.5 20.3±13.4 
14.3±4.1 17.2±12.4 29.2±7.8 27.3±20.2 
Chloroquine 4.1±1.8 6.2±1.8 6.8±3.3 7.8±2.1 
63.8±30.1 84.6±35.6 99.3±45.3 131.8±33.6 
 
Table 1: Inhibitory concentrations IC50 and IC90 (in nM) of selected dyes and chloroquine 
against the culture-adapted strain of P. falciparum 3D7 or Dd2 (grey highlight). Each value is 
the geometric mean IC of at least 3 independent experiments. 
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2.2. Activity of DiOC6 and Rhodamine B against P. berghei in mice 
In the previous experiments, five dyes with good antiplasmodial activity and a good 
selectivity index were identified. The next step was to test their activity in vitro in a 
mouse model. It was decided not to test SYTO 9 and Hoechst 33342 because of the 
risk of mutation as they target nucleic acids. Since MitoTracker Red and Rhodamine 
B are both Rhodamine dyes, it was decided to pilot the experiment with Rhodamine 
B, a compound which is still being used in cosmetics in some countries although it 
has been removed from the FDA color additive status list since 1983 [42]. In addition, 
DiOC6 was tested as well. 
2.2.1. Evaluation of the toxicity of DiOC6 and Rhodamine B 
Three female CD1 swiss mice received one dose of 40mg/kg of DiOC6 i.p. Two mice 
died within 2h after receiving DiOC6. The third one died 24h after the injection. 
The three mice who received 15mg/kg of Rhodamine B were monitored for four days. 
There was no significant change in the weight and mice behaved normally.  
2.2.2. Evaluation of the efficacy in vivo 
Two groups of nine mice were infected i.v. with 2.107 P. berghei infected 
erythrocytes. Two hours later, the mice received either 15mg/kg of Rhodamine B in 
0.3mL or the same volume of injection solution (7% Tween 80/3% Ethanol). Mice 
continued to receive the same treatment every day for three days and their 
parasitaemia was monitored until four days after infection. Parasitaemia was 
determined by thin blood smear microscopy. Three days after infection, two mice who 
received Rhodamine B died, four days after infection another four mice died. In 
comparison, all the mice from the control group survived until the end of the 
experiment (4 days after the infection). There was no reduction in parasitaemia in the 
Rhodamine B group compared to the control group (Figure 3). 
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Figure 3: Parasitaemia counted by thin blood smear microscopy over time in the 
group of mice treated with Rhodamine B compared to the control group. 
 
2.3. Prospective evaluation of artemether-lumefantrine for the treatment of 
non-falciparum and mixed-species malaria in Gabon (publication 2) 
2.3.1. Published results 
The study was conducted at the Centre de Recherches Médicales de Lambaréné 
(CERMEL) and the hospital of Fougamou in Gabon. Subjects were recruited after 
giving their written informed consent if they presented fever or history of fever in the 
last four days and if non-falciparum or mixed-species (including P. falciparum) 
Plasmodium infection was confirmed by microscopy of thick blood smears (TBS). 
Subjects were excluded if they required hospitalization, in case of previous 
hypersensitivity to artemether- lumefantrine, pregnancy or breastfeeding or prior use 
of other antimalarial medication. A total of forty subjects were included in the study 
between July 2008 and July 2010. One subject withdrew his consent before the 
initiation and one subject was not included in the final analysis because of 
concomitant use of chloroquine. Subjects received an oral treatment consisting of six 
doses of artemether-lumefantrine (Coartem®) over three consecutive days. TBS and 
blood dried on filter paper were prepared 0, 8, 24, 36, 48 and 60 hours following start 
of treatment and subsequently during the follow-up visits at Days 7, 14 and 28 after 
inclusion.  
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To validate thick blood smear readings and confirm the presence of the reported 
malaria species, DNA was extracted from the filter papers and used to amplify a 
species specific fragment of the 18S rRNA gene by nested PCR according to 
standard procedures [1,43,44]. For some samples nested PCR failed to amplify a 
fragment of the 18S rRNA gene. In this case a nested PCR was carried out to amplify 
a fragment of the genes coding for caseinolytic protease C (clpC) and cytochrome B 
(cytB). Subsequently, PCR products were sequenced by the Sanger method to 
identify the parasite species [45]. Only 19 samples out of 39 were confirmed as non-
falciparum or mixed infection. The remaining 20 samples contained only P. 
falciparum DNA. Out of the 19 samples positive for non-falciparum species, one was 
a P. malariae mono-infection. The rest contained mixed infection with P. falciparum 
and P. ovale (12 samples, 63%), P. falciparum and P. malariae (3 samples, 16%) 
and P. falciparum, P. malariae and P. ovale occurring simultaneously (3 samples, 
16%). P. ovale curtisi and P. ovale walikeri were also detected in nine and ten 
samples, respectively and appeared concurrently in four samples.    
The median parasite clearance time, evaluated by microscopy of TBS, was 24h after 
initiation of treatment and all patients were microscopically negative after 48h. All 
patients who presented with fever (n=5) cleared fever within 36h. The overall cure 
rate was 100% (95% CI: 91-100%). No serious adverse events occurred during the 
study and eight patients experienced adverse events from which five were of mild 
severity and three were of moderate severity. Only one adverse event was 
considered as possible drug related (vomiting at Day 1 after beginning of treatment).  
2.3.2. Non-published results 
For three samples, the sequencing of the product of the 1st step of the nested PCR of 
the 18S rRNA gene showed presence of an additional Plasmodium species with the 
best sequence alignment to the 18S rRNA gene from Plasmodium berghei (P. 
berghei) with 95 to 99% identity (See Figure 4). Sequencing of the clpC and the cytB 
gene from these samples showed the presence of P. falciparum and P. ovale. This 
finding is currently investigated using next generation sequencing methodology as 
well as additional sampling in the same region as the original study.  
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3. Discussion 
3.1. In vitro activity of fluorescent dyes against asexual blood stages of 
Plasmodium falciparum (publication 1) 
Synthetic dyes represent a valuable source of chemotherapeutics as Paul Guttmann 
and Paul Ehrlich showed more than one century ago when they successfully cured 
two malaria patients with methylene blue [37]. In the present proof of principle study 
five out of 14 compounds showed high antiplasmodial activity. Three of them stain 
specifically the mitochondrion (MitoTracker Red, Rhodamine B, DiOC6) and two stain 
specifically nucleic acids (Hoechst 33342, SYTO 9). MitoTracker Red is a Rhodamine 
based dye such as MitoTracker Green. Although antiparasitic activity of other 
Rhodamine dyes has been shown previously, this is the first time that these two dyes 
are studied. Contrary to what was previously reported, it was found that Rhodamine 
B was more active than Rhodamine 123 which could be explained by the fact that a 
different derivative (a hexyl ester) of the Rhodamine B was used in this study [46]. 
The molecule is positively charged and therefore able to accumulate specifically in 
the mitochondrion [47]. Unfortunately, when tested in a mouse model, Rhodamine B 
was not active and showed signs of toxicity. DiOC6 is a lipophilic green fluorescent 
dye that accumulates in metabolically active mitochondria. It can reversibly impair 
mitochondrion functions in yeast [48], which could explain the higher IC50 in the 6-day 
experiment performed with Dd2. In the 6-day experiment, a fraction of the drug was 
removed without replacement after two days of incubation, allowing the recovery and 
growth of the parasites until Day 6. Although it has a good selectivity index, it was 
shown to be highly toxic in mice. Hoechst 33342 and SYTO 9 are two nucleic acids 
stains. Hoechst 33342 is a non-intercalating agent with a preference for AT rich 
region which could explain its specificity for the AT rich Plasmodium genome. 
Moreover, Hoechst 33258, a related dye, was previously shown to be antiparasitic as 
well [49]. Hoechst 33342 contains an additional ethyl group, rendering it more 
lipophilic and thus more membrane permeable than Hoechst 33258, which may 
explain the better antiplasmodial activity of Hoechst 33342.  
With this study five molecules with good antiplasmodial activity which do not belong 
to chemotypes currently in current clinical use were identified. Although the activity of 
two of these compounds was not further confirmed in vivo in a mouse model, it 
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shows that prescreening for staining properties may be an interesting way to build 
restricted pathogen-specific compound libraries.  
JC1, MitoTracker Green, Rhodamine 123, and Daspei had low antiplasmodial activity 
and are therefore unlikely to be further developed as antimalarial drugs. SYTO 18, 
acridine orange, SYBR green I, CFDA, and CFDA-SE showed very low or no 
antiplasmodial activity compared to chloroquine or methylene blue. This observation 
may however have interesting implications for the development of new methods to 
track parasites with minimal interference with their viability.  
In conclusion, five dyes, Hoechst 33342, MitoTracker Red, DiOC6, SYTO 9, and 
Rhodamine B, show high antiplasmodial activity in vitro and low cytotoxicity against 
human HeLa cells. However, when further tested in a mouse model, Rhodamine B 
and DiOC6 were found to be toxic. On the other side of the spectrum, dyes with low 
toxicity against P. falciparum can be used to stain parasites without interfering with 
cell growth or metabolism. 
 
3.2. A prospective evaluation of artemether-lumefantrine for the treatment of 
non-falciparum and mixed-species malaria in Gabon (publication 2) 
This study is the first systematic and prospective evaluation of the efficacy of 
artemether-lumefantrine against P. malariae, P. ovale or mixed species malaria 
infection. Treatment resulted in rapid parasite clearance and a 100% cure rate after 
28 days, which confirms the primary hypothesis of an adequate clinical and 
parasitological response rate above 90%.  
One of the limitations of the study is the poor performance of microscopy against 
molecular diagnostic to identify non-falciparum species, which led to an over-estimate 
of the number of patient infected with non-falciparum or mixed species malaria. This 
is however not completely unexpected because of the difficult assessment of 
parasites species by thick blood smear microscopy. This may be partly due to the 
fact that non-falciparum species often present with low parasitaemia and P. 
falciparum predominates in mixed species infection. In our context the laboratory 
undergoes internal and external quality control, moreover a senior expert 
microscopist was available to decide on ambiguous samples. Despite this, the 
discrepancy with the PCR results were still unexpectedly high. This shows that the 
misclassification of malaria species is high in an African routine setting and may be 
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even higher in laboratories without adequate quality management. This emphasizes 
the need for a single treatment to cure all malaria species. In Gabon, where the 
prevalence of chloroquine resistance is almost 100% [50], misclassification of malaria 
species is likely to lead to treatment failure and can be dangerous for the patient. The 
present study is the first to systematically show the efficacy of artemether-
lumefantrine in non-falciparum and mixed-species malaria and encourage the use of 
this drug as single therapy for the treatment of all cases of malaria. Further studies 
are still needed notably with a bigger samples size and with the comparison with a 
control group between chloroquine and artemether-lumefantrine for the treatment of 
mono-infection with non-falciparum species.  
3.3. Non published data 
 In three samples for which the nested PCR amplicon of the ssurRNA was 
sequenced, I found that the best alignment was with a sequence of the P. berghei 
18S rRNA gene.  P. berghei is a murine malaria parasite which is not known to infect 
human. These results are difficult to explain however it is unlikely to be a 
contamination as we do not work with P. berghei in the laboratory. Moreover, only 
viable parasites are usually detected in the blood by PCR. Therefore it is suggestive 
that the result is the consequence of a zoonotic infection. Further work is being 
conducted to reproduce and confirm these results. Besides detailed analysis using 
next generation sequencing methods to identify other samples with similar parasites, 
a new study on non-falciparum parasites in malaria patients and potential animal 
reservoirs (small ruminants and bats) has been initiated. These investigations are still 
ongoing and results are expected by the end of 2016.   
4. Conclusion 
 
There is a need for broadly acting antimalarial drugs. This requirement includes multi-
stage activity as well as activity against different parasite species. AL showed very 
good activity against different species, but does not act against pre-erythrocytic 
stages and reduces gametocytes only modestly. Dyes are a group of chemically 
heterogeneous compounds that may extent the spectrum of activity. In fact, the dye 
methylene blue was shown to meet many of the requirements. Investigation of larger 
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dye libraries may result in highly interesting novel antimalarial compounds and may 
lead to the development of novel, broadly acting drugs. The use of such drug would 
not only reduce dramatically the transmission of the parasite but also prevent the 
development of resistance and would therefore have a huge impact of malaria control 
and elimination.  
 
5. Material and Method for unpublished data 
5.1. Biological material 
I used the P. berghei ANKA cl15cy1 strain (Malaria Research and Reference 
Reagents Resource center, ATCC) and female mouse (mus musculus) from the 
strain Swiss (CD1) purchased from Charles River (Sulzfeld). The protocol has been 
approved by the Regierungspräsidium Tübingen.  
5.2. Evaluation of the toxicity of DiOC6 and Rhodamine B 
Three mice were injected intraperitoneally (i.p.) with either 15mg/kg of Rhodamine B 
or 40mg/kg of DiOC6. The compounds were diluted in a sterile solution of 7% tween 
80 and 3% ethanol. The health status of the mice was monitored 30 minutes and 2h 
post injections then once a day for four days and notably weight was recorded every 
day. In case of severe degradation of health status and weight loss >30%, mice were 
euthanatized before day 4 by CO2 asphyxia and neck dislocation.    
5.3. Evaluation of the activity in vitro of DiOC6 and Rhodamine B 
I used the method described by Fidock et al [51]. Briefly, nine mice per group were 
injected intravenously with 2.107 P.berghei ANKA cl15cy1 parasites. After 2-4h, they 
received a single dose of either Rhodamine B (Hexyl ester, Invitrogen), DiOC6 
(Invitrogen) i.p. (15mg/kg and 40mg/kg respectively) or an equivalent volume of 
injection solution (7% tween 80 and 3% ethanol). The mice received the same 
treatment every day for four days. The weight as well as the general health status 
was monitored. Moreover, about 10µL of blood were taken every day from the end of 
the tail in order to prepare thin blood smear. Thin blood smear were stained for 20 
minutes in 5% Giemsa solution after methanol fixation. Parasitaemia was estimated 
by counting at least 1000 erythrocytes on a Giemsa-stained thin blood film. To 
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calculate treatment efficacy, the area under the curve (AUC) until Day 4 was 
calculated using the trapezoidal rule. The ratio of sums of AUCs was used to 
calculate anti-parasitic efficacy of the compounds in percent. 
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6. Personal contribution 
 
Publication “In Vitro Activity of Fluorescent Dyes against Asexual Blood 
Stages of Plasmodium falciparum” 
- In vitro culture of Dd2 and 3D7 P. falciparum parasites 
- Drug inhibition assay 
- HRP2 ELISA 
- Neutral red assay 
- Statistical analysis 
- Preparation of the manuscript 
Activity of Rhodamine B and DiOC6 against P. berghei in mice 
- Toxicity test on mice 
- P. berghei rodent malaria 4-days suppressive test 
- Statistical analysis 
Publication “A prospective evaluation of artemether-lumefantrine for the 
treatment of non-falciparum and mixed-species malaria in Gabon” 
- DNA extraction from dried blood spot 
- Establishing PCR for species identification 
- Species identification by PCR 
- Species identification by sequencing 
- Drafting of the manuscript 
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